Management of Rheumatic Heart Disease with Mitral Stenosis

Introduction to Management

The European Society of Cardiology recommends initiating lifelong secondary antibiotic prophylaxis with benzathine penicillin G 1.2 million units IM every 4 weeks, providing symptom control with diuretics and heart rate control agents, anticoagulating if atrial fibrillation or thromboembolic risk factors are present, and performing percutaneous mitral balloon commissurotomy (PMBC) for symptomatic severe stenosis with favorable valve morphology 1, 2, 3

The American Heart Association recommends that all patients with rheumatic heart disease require long-term antibiotic prophylaxis to prevent recurrent acute rheumatic fever, which accelerates valve damage 2
Benzathine penicillin G 1.2 million units IM every 4 weeks is the gold standard regimen with the strongest evidence for preventing recurrences 2
Duration should be ≥10 years after the last attack OR until age 40 (whichever is longer) for patients with persistent valvular disease 4, 2
For penicillin-allergic patients, alternatives include oral penicillin V, sulfadiazine, or macrolide antibiotics 2
Prophylaxis must continue even after valve surgery, a critical pitfall that is frequently overlooked but explicitly recommended 4

The European Society of Cardiology recommends heart rate control is essential for symptom relief, particularly in patients with atrial fibrillation or during exertion 1, 3
Beta-blockers or non-dihydropyridine calcium channel blockers are first-line for rate control 1, 3
Digoxin is specifically recommended for rate control in atrial fibrillation with mitral stenosis 3

Diuretics are indicated for symptom relief when pulmonary edema or congestion is present, particularly important as mitral stenosis causes elevated left atrial pressure and pulmonary congestion 1, 3

Anticoagulation with vitamin K antagonists (INR 2-3) is mandatory in specific high-risk scenarios, including all patients with atrial fibrillation and moderate-to-severe mitral stenosis 1, 3
History of systemic thromboembolism, presence of left atrial thrombus on imaging, dense spontaneous echo contrast in the left atrium, and severely dilated left atrium are also indications for anticoagulation 1, 3
Vitamin K antagonists, not NOACs, are recommended for anticoagulation in rheumatic mitral stenosis 3

PMBC at a comprehensive valve center is the preferred intervention for rheumatic mitral stenosis when symptomatic patients have severe mitral stenosis (MVA ≤1.5 cm²) with favorable valve morphology 1, 2, 3
Asymptomatic patients with severe stenosis and new-onset atrial fibrillation, pulmonary artery systolic pressure >50 mmHg at rest, high thromboembolic risk, or planning pregnancy are also candidates for PMBC 1, 3, 2

Mitral valve surgery is indicated when patients are not suitable for PMBC due to unfavorable valve anatomy, moderate-to-severe mitral regurgitation, left atrial thrombus, or previous failed PMBC 1, 5
Bioprosthetic valve rather than mechanical is recommended for women of childbearing age requiring valve replacement to avoid anticoagulation hazards during pregnancy 1

Regular echocardiographic monitoring is essential to detect disease progression, with frequency depending on severity of mitral stenosis 2, 3
Severe mitral stenosis requires monitoring every 6-12 months, moderate every 1-2 years, and mild every 3-5 years 2, 3

Women with severe mitral stenosis should avoid pregnancy until the valve disease is treated, and pre-pregnancy evaluation and intervention should be performed in asymptomatic patients with severe stenosis 5, 4, 2
Beta-blockers and diuretics are recommended during pregnancy for heart rate control and volume overload, and cardiac surgery may be necessary if medical and interventional therapies fail 4

Guideline-directed medical therapy, including ACE inhibitors/ARBs, beta-blockers, aldosterone antagonists, and sacubitril/valsartan, should be implemented in patients with left ventricular systolic dysfunction 2
Careful blood pressure management is essential, avoiding abrupt BP lowering in stenotic lesions 2

Infective endocarditis prophylaxis with antibiotic prophylaxis before dental procedures is recommended, but not needed if patient is already on secondary prophylaxis antibiotics 2
Influenza and pneumococcal vaccinations are recommended, and optimal oral health maintenance is essential to reduce endocarditis risk 2

Discontinuing secondary antibiotic prophylaxis too early, using NOACs instead of warfarin, inadequate anticoagulation monitoring, failure to recognize pregnancy as a high-risk period, assuming medical therapy alone is sufficient, and neglecting regular follow-up echocardiography are common pitfalls to avoid 4, 2, 3